A Phase 1, Open Label Study to Characterize the Absorption, Metabolism and Excretion of 14C-JNJ-53718678 After a Single Dose in Healthy Adult Male Subjects
Latest Information Update: 18 Dec 2019
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 12 Dec 2019 Results, quantifying the elimination pathways of JNJ-53718678 by integrating duodenal sampling in human mass balance study, published in the Advances in Therapy
- 14 Apr 2017 Status changed from recruiting to completed.
- 01 Mar 2017 Status changed from not yet recruiting to recruiting.